Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
Status:
Unknown status
Trial end date:
2019-08-17
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study.
Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study
will include approximately 176 randomized subjects with inflammatory lesions of
papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at
Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will
be up to 20 study sites in the USA.